NCT03883906View on ClinicalTrials.gov

Donor-Derived Viral Specific T-cells (VSTs) for Prophylaxis Against Viral Infections After Allogeneic Stem Cell Transplant

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 16, 2019

Primary Completion Date

October 31, 2020

Study Completion Date

October 1, 2021

Conditions
Allogeneic Stem Cell TransplantViral Infection
Interventions
BIOLOGICAL

Viral Specific T-cells (VSTs)

VSTs will be infused into stem cell transplant recipients

Trial Locations (1)

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

All Listed Sponsors
collaborator

Hoxworth Blood Center

OTHER

lead

Children's Hospital Medical Center, Cincinnati

OTHER

NCT03883906 - Donor-Derived Viral Specific T-cells (VSTs) for Prophylaxis Against Viral Infections After Allogeneic Stem Cell Transplant | Biotech Hunter | Biotech Hunter